Proteome Sciences (PRM) Competitors

Proteome Sciences logo
GBX 1.04 -0.13 (-11.11%)
As of 11/20/2026 12:40 PM Eastern

PRM vs. YGEN, GDR, VRCI, AGL, and GENI

Should you buy Proteome Sciences stock or one of its competitors? Proteome Sciences's main competitors and comparable companies include Yourgene Health (YGEN), genedrive (GDR), Verici Dx (VRCI), ANGLE (AGL), and GENinCode (GENI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Proteome Sciences compare to Yourgene Health?

Yourgene Health (LON:YGEN) and Proteome Sciences (LON:PRM) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

Proteome Sciences has lower revenue, but higher earnings than Yourgene Health. Proteome Sciences is trading at a lower price-to-earnings ratio than Yourgene Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Yourgene Health£29.67M0.00-£8.17M-£0.01N/A
Proteome Sciences£3.77M0.97-£4.08M-£0.72N/A

Yourgene Health has a net margin of -27.55% compared to Proteome Sciences' net margin of -61.46%. Proteome Sciences' return on equity of 23.85% beat Yourgene Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Yourgene Health-27.55% -27.06% -6.71%
Proteome Sciences -61.46%23.85%-19.25%

23.3% of Yourgene Health shares are owned by institutional investors. Comparatively, 0.0% of Proteome Sciences shares are owned by institutional investors. 64.4% of Yourgene Health shares are owned by company insiders. Comparatively, 36.7% of Proteome Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Yourgene Health has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, Proteome Sciences has a beta of 0.157, indicating that its stock price is 84% less volatile than the broader market.

In the previous week, Yourgene Health's average media sentiment score of 0.00 equaled Proteome Sciences'average media sentiment score.

Company Overall Sentiment
Yourgene Health Neutral
Proteome Sciences Neutral

Summary

Yourgene Health beats Proteome Sciences on 7 of the 10 factors compared between the two stocks.

How does Proteome Sciences compare to genedrive?

genedrive (LON:GDR) and Proteome Sciences (LON:PRM) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

0.1% of genedrive shares are held by institutional investors. Comparatively, 0.0% of Proteome Sciences shares are held by institutional investors. 28.1% of genedrive shares are held by company insiders. Comparatively, 36.7% of Proteome Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, genedrive's average media sentiment score of 0.67 beat Proteome Sciences' score of 0.00 indicating that genedrive is being referred to more favorably in the media.

Company Overall Sentiment
genedrive Positive
Proteome Sciences Neutral

Proteome Sciences has higher revenue and earnings than genedrive. Proteome Sciences is trading at a lower price-to-earnings ratio than genedrive, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
genedrive£929K14.43-£21.22M-£0.79N/A
Proteome Sciences£3.77M0.97-£4.08M-£0.72N/A

genedrive has a beta of 1.004, meaning that its share price is 0% more volatile than the broader market. Comparatively, Proteome Sciences has a beta of 0.157, meaning that its share price is 84% less volatile than the broader market.

Proteome Sciences has a net margin of -61.46% compared to genedrive's net margin of -500.75%. Proteome Sciences' return on equity of 23.85% beat genedrive's return on equity.

Company Net Margins Return on Equity Return on Assets
genedrive-500.75% -1,044.57% -74.09%
Proteome Sciences -61.46%23.85%-19.25%

Summary

Proteome Sciences beats genedrive on 7 of the 12 factors compared between the two stocks.

How does Proteome Sciences compare to Verici Dx?

Proteome Sciences (LON:PRM) and Verici Dx (LON:VRCI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Proteome Sciences has a net margin of -61.46% compared to Verici Dx's net margin of -223.60%. Proteome Sciences' return on equity of 23.85% beat Verici Dx's return on equity.

Company Net Margins Return on Equity Return on Assets
Proteome Sciences-61.46% 23.85% -19.25%
Verici Dx -223.60%-127.57%-26.14%

0.0% of Proteome Sciences shares are owned by institutional investors. Comparatively, 9.9% of Verici Dx shares are owned by institutional investors. 36.7% of Proteome Sciences shares are owned by company insiders. Comparatively, 1.1% of Verici Dx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Proteome Sciences' average media sentiment score of 0.00 equaled Verici Dx'saverage media sentiment score.

Company Overall Sentiment
Proteome Sciences Neutral
Verici Dx Neutral

Proteome Sciences has a beta of 0.157, indicating that its share price is 84% less volatile than the broader market. Comparatively, Verici Dx has a beta of 1.222, indicating that its share price is 22% more volatile than the broader market.

Proteome Sciences has higher revenue and earnings than Verici Dx. Proteome Sciences is trading at a lower price-to-earnings ratio than Verici Dx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Proteome Sciences£3.77M0.97-£4.08M-£0.72N/A
Verici Dx£3.52M3.37-£6.56M£0.101.78

Summary

Proteome Sciences beats Verici Dx on 6 of the 11 factors compared between the two stocks.

How does Proteome Sciences compare to ANGLE?

ANGLE (LON:AGL) and Proteome Sciences (LON:PRM) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership.

Proteome Sciences has a net margin of -61.46% compared to ANGLE's net margin of -1,560.86%. Proteome Sciences' return on equity of 23.85% beat ANGLE's return on equity.

Company Net Margins Return on Equity Return on Assets
ANGLE-1,560.86% -157.49% -29.89%
Proteome Sciences -61.46%23.85%-19.25%

ANGLE has a beta of 0.22, indicating that its share price is 78% less volatile than the broader market. Comparatively, Proteome Sciences has a beta of 0.157, indicating that its share price is 84% less volatile than the broader market.

In the previous week, ANGLE's average media sentiment score of 0.00 equaled Proteome Sciences'average media sentiment score.

Company Overall Sentiment
ANGLE Neutral
Proteome Sciences Neutral

17.5% of ANGLE shares are owned by institutional investors. Comparatively, 0.0% of Proteome Sciences shares are owned by institutional investors. 2.7% of ANGLE shares are owned by company insiders. Comparatively, 36.7% of Proteome Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Proteome Sciences has higher revenue and earnings than ANGLE. Proteome Sciences is trading at a lower price-to-earnings ratio than ANGLE, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ANGLE£2.62M2.89-£21.76M-£4.80N/A
Proteome Sciences£3.77M0.97-£4.08M-£0.72N/A

Summary

Proteome Sciences beats ANGLE on 7 of the 11 factors compared between the two stocks.

How does Proteome Sciences compare to GENinCode?

GENinCode (LON:GENI) and Proteome Sciences (LON:PRM) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

Proteome Sciences has higher revenue and earnings than GENinCode. Proteome Sciences is trading at a lower price-to-earnings ratio than GENinCode, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GENinCode£2.60M1.62-£6.10M-£1.27N/A
Proteome Sciences£3.77M0.97-£4.08M-£0.72N/A

In the previous week, GENinCode's average media sentiment score of 0.00 equaled Proteome Sciences'average media sentiment score.

Company Overall Sentiment
GENinCode Neutral
Proteome Sciences Neutral

GENinCode has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market. Comparatively, Proteome Sciences has a beta of 0.157, suggesting that its share price is 84% less volatile than the broader market.

Proteome Sciences has a net margin of -61.46% compared to GENinCode's net margin of -202.42%. Proteome Sciences' return on equity of 23.85% beat GENinCode's return on equity.

Company Net Margins Return on Equity Return on Assets
GENinCode-202.42% -481.34% -63.99%
Proteome Sciences -61.46%23.85%-19.25%

2.8% of GENinCode shares are owned by institutional investors. Comparatively, 0.0% of Proteome Sciences shares are owned by institutional investors. 8.4% of GENinCode shares are owned by insiders. Comparatively, 36.7% of Proteome Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Proteome Sciences beats GENinCode on 7 of the 11 factors compared between the two stocks.

Get Proteome Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for PRM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

PRM vs. The Competition

MetricProteome SciencesLife Sciences Tools & Services IndustryHealthcare SectorLON Exchange
Market Cap£3.65M£10.69B£7.78B£2.67B
Dividend Yield6.17%1.46%2.47%5.11%
P/E Ratio-1.4448.9233.2222.78
Price / Sales0.978.468.104.91
Price / Cash3.7326.5521.0120.23
Price / Book-0.584.194.262.40
Net Income-£4.08M£56.66B£3.50B£5.88B
1 Month Performance-29.73%-7.81%-10.48%-4.75%
1 Year Performance-47.74%11.09%-4.61%5.15%

Proteome Sciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PRM
Proteome Sciences
N/AGBX 1.04
-11.1%
N/A-24.0%£3.65M£3.77MN/A240
YGEN
Yourgene Health
N/AN/AN/AN/A£16.43M£29.67MN/A253
GDR
genedrive
N/AGBX 0.90
-0.6%
N/A-11.0%£14.37M£929KN/A43
VRCI
Verici Dx
N/AGBX 0.18
-4.2%
N/A-73.7%£12.13M£3.52M1.8219
AGL
ANGLE
N/AGBX 2.35
-11.3%
N/A+0.0%£7.58M£2.62MN/A650

Related Companies and Tools


This page (LON:PRM) was last updated on 11/21/2026 by MarketBeat.com Staff.
From Our Partners